Shares of ImmuPharma plc (LON:IMM – Get Free Report) shot up 21.2% on Friday. The company traded as high as GBX 4.50 and last traded at GBX 4. Approximately 7,844,468 shares traded hands during mid-day trading, an increase of 220% from the average daily volume of 2,450,626 shares. The stock had previously closed at GBX 3.30.
ImmuPharma Stock Up 21.2%
The stock has a market cap of £25.01 million, a P/E ratio of -4.82 and a beta of 3.01. The business has a 50-day simple moving average of GBX 3.64 and a 200-day simple moving average of GBX 4.10.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. On average, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
